Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to 0.29.

  • Exagen's Equity Ratio fell 216.46% to 0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29, marking a year-over-year decrease of 216.46%. This contributed to the annual value of 0.21 for FY2024, which is 4643.46% down from last year.
  • As of Q3 2025, Exagen's Equity Ratio stood at 0.29, which was down 216.46% from 0.36 recorded in Q2 2025.
  • Over the past 5 years, Exagen's Equity Ratio peaked at 0.74 during Q1 2021, and registered a low of 0.16 during Q1 2025.
  • Over the past 5 years, Exagen's median Equity Ratio value was 0.45 (recorded in 2023), while the average stood at 0.47.
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 2888.86% in 2021, then tumbled by 5961.31% in 2025.
  • Exagen's Equity Ratio (Quarter) stood at 0.69 in 2021, then decreased by 28.43% to 0.49 in 2022, then dropped by 19.07% to 0.4 in 2023, then plummeted by 46.43% to 0.21 in 2024, then surged by 35.25% to 0.29 in 2025.
  • Its last three reported values are 0.29 in Q3 2025, 0.36 for Q2 2025, and 0.16 during Q1 2025.